Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

diethylpropion hydrochloride

TENUATE

diethylpropion hydrochloride (TENUATE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 20
News articles 0
Drug details — diethylpropion hydrochloride
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
20
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

diethylpropion hydrochloride (TENUATE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN diethylpropion hydrochloride
Brand TENUATE
Mechanism Norepinephrine transporter inhibitor
Target Sodium-dependent dopamine transporter
Route ORAL
Formulation TABLET, EXTENDED RELEASE
Originator Teva Pharma GmbH

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Sodium-dependent dopamine transporter

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. CYD32 Phase 3 · Sanofi Pasteur MSD · Dengue Fever
  2. DEN-303 Phase 3 · Takeda · Dengue Fever
  3. Investigational live attenuated mumps vaccine Phase 3 · Sinovac Research and · Mumps
  4. Live attenuated Japanese encephalitis chimeric virus vaccine Phase 3 · Sanofi Pasteur MSD · Japanese Encephalitis
  5. Live attenuated SA 14-14-2 vaccine Phase 3 · Repatha · Encephalitis, Japanese B
  6. Live-Attenuated influenza Vaccine(LAIV) Phase 3 · BRIGHT MINDS BIOSCIENCES · Influenza
  7. Metalyse 5 000 units (25 mg) powder for solution for injection Phase 3 · PARItec · Adult patients with a LVOS with large core within 9 hours of
  8. Oka strain varicella attenuated live vaccine Phase 3 · Chinese Academy of · Chickenpox Vaccines

Related & competitor drugs

Browse all drugs
  1. amphetamine adipate Dopamine transporter releasing agent
  2. amphetamine aspartate Norepinephrine transporter releasing agent
  3. amphetamine sulfate Norepinephrine transporter releasing agent
  4. armodafinil Dopamine transporter inhibitor
  5. bupropion hydrochloride Dopamine transporter inhibitor
  6. dexmethylphenidate hydrochloride Norepinephrine transporter inhibitor

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12383566

    Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12102671

    Method of vaccination with an attenuated RSV vaccine formulation

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12054519

    Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11813319

    Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11801296

    Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11793870

    Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11730801

    Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11478517

    Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11331383

    Attenuated african swine fever virus vaccine

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11318196

    Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11202825

    Attenuated infectious bronchitis virus

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11197923

    Methods and compositions for live attenuated viruses

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11135236

    Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11117975

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11007263

    Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10980872

    Genetically stable live attenuated respiratory syncytial virus vaccine and its production

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10981986

    Fusions of antibodies to CD38 and attenuated interferon alpha

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10806781

    Compositions and methods for live, attenuated alphavirus formulations

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10596247

    Methods and compositions for attenuated chlamydia as vaccine and vector

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is diethylpropion hydrochloride?

diethylpropion hydrochloride (TENUATE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for diethylpropion hydrochloride?

TENUATE is a marketed brand name for diethylpropion hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of diethylpropion hydrochloride?

diethylpropion hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.